What does Adlai nortye do?

Adlai Nortye focuses on discovering and developing important new treatments for cancer with a mission to improve patient lives by identifying and developing differentiated innovative medicines that help people live better, live longer.

Who offered Adlai nortye ads?

All of the ADSs were offered by Adlai Nortye. In addition, Nippon Kayaku Co., Ltd., a chemical company headquartered in Japan, acquired a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price.

Does Adlai nortye have a IPO?

Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell cancer. The global market for head and neck cancer treatments is expected to reach $3.5 billion by 2030.